Journal
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Volume 320, Issue 5, Pages R697-R703Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpregu.00338.2020
Keywords
amylin; antibody; CGRP; cross-reactivity; pancreas
Categories
Funding
- Marsden Fund (Royal Society of New Zealand)
- Royal Society of New Zealand
- Health Research Council (New Zealand)
- University of Auckland
Ask authors/readers for more resources
This study found that current amylin antibodies frequently cross-react with CGRP, making them unsuitable for use in tissues that highly express CGRP. Therefore, previous studies using these antibodies should be reevaluated in light of these findings.
Amylin is a 37-amino acid endocrine hormone secreted from the pancreas in response to nutrient intake, acting centrally to promote meal-ending satiation. With many studies linking amylin action to the nervous system, determining the distribution or expression of amylin in the nervous system is critical. However, amylin shares sequence identity and structural homology to the related neuropeptide calcitonin gene-related peptide (CGRP). This creates challenges in identifying selective amylin antibodies that do not cross-react with CGRP, especially in neural tissues, where CGRP is densely packed into secretory vesicles. Here, we characterized eight amylin antibodies to determine their ability to detect amylin and cross-react with rat or human alpha CGRP, using immunoblots and preabsorption controls in rat pancreas. We observed that amylin antibodies frequently cross-reacted with alpha CGRP and are therefore not suitable for use in tissues that highly express CGRP. Earlier work using these antibodies should be revisited in light of our findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available